<DOC>
	<DOCNO>NCT00911222</DOCNO>
	<brief_summary>The purpose registry record information reality anti-emetic therapy cancer-patients Germany . The outcome study efficacy anti-emetic therapy dependent rate `` complete major control '' nausea emesis moderately highly emetogenic chemotherapy , consist platin-derivates ( cisplatin , carboplatin oxaliplatin ) , anthracyclines and/or cyclophosphamid .</brief_summary>
	<brief_title>Epidemiological EMESIS-Registry</brief_title>
	<detailed_description />
	<mesh_term>Antiemetics</mesh_term>
	<criteria>Moderately highly emetogenic chemotherapy consist platinderivates ( cisplatin , carboplatin oxaliplatin ) , anthracyclines and/or cyclophosphamid . start 1st cycle regimen ( chemo naive patient ) . Inclusion pretreated patient also possible , last treatment cycle previous chemotherapy give &gt; = 24 month ago . Compliance registry procedure Age &gt; = 18 year WHO Performance Status 0 1 ( KarnofskyIndex &gt; = 70 % ) Life expectancy least 12 week Signed date informed consent start registry Mentally incapable incompliant patient Last chemotherapy &lt; = 24 month ( pretreated ) Known hypersensitivity antiemetic medication unability patient treat oral medication pregnancy lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>antiemetic therapy</keyword>
	<keyword>emesis</keyword>
	<keyword>vomit</keyword>
	<keyword>nausea</keyword>
	<keyword>moderately highly emetogenic chemotherapy</keyword>
	<keyword>cisplatin</keyword>
	<keyword>carboplatin</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>anthracycline</keyword>
	<keyword>cyclophosphamid</keyword>
</DOC>